<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04947631</url>
  </required_header>
  <id_info>
    <org_study_id>DKF-313-P3</org_study_id>
    <nct_id>NCT04947631</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia</brief_title>
  <official_title>A Multi-center, Randomized, Double-blinded, Double-dummy, Parallel Group, 48-week, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongkook Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dongkook Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blinded, double-dummy, parallel group, 48-week&#xD;
      study to evaluated the efficacy and safety of DKF-313 (dutasteride and tadalafil) in patients&#xD;
      with benign prostatic hyperplasia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is conducted to access whether DKF-313 once daily for 48 weeks is superior to&#xD;
      dutasteride 0.5 mg once daily and tadalafil 5 mg once daily each in improving BPH-LUTS as&#xD;
      measured by changes in IPSS total scores.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total International Prostate Symptom Score (IPSS) from baseline to Week 48</measure>
    <time_frame>Weeks 0 and 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total International Prostate Symptom Score (IPSS) from baseline to Weeks 4, 12, 24 and 36</measure>
    <time_frame>Weeks 0, 4, 12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total International Prostate Symptom Score (IPSS) voiding (obstructive) subscores from baseline to Weeks 4, 12, 24, 36 and 48</measure>
    <time_frame>Weeks 0, 4, 12, 24, 36 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total International Prostate Symptom Score (IPSS) storage (irritative) subscores from baseline to Weeks 4, 12, 24, 36 and 48</measure>
    <time_frame>Weeks 0, 4, 12, 24, 36 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total International Prostate Symptom Score (IPSS) Quality of Life (QoL) index from baseline to Weeks 4, 12, 24, 36 and 48</measure>
    <time_frame>Weeks 0, 4, 12, 24, 36 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Qmax from baseline to Weeks 24 and 48</measure>
    <time_frame>Weeks 0, 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in post void residual (PVR) volume from baseline to Weeks 24 and 48</measure>
    <time_frame>Weeks 0, 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in prostate volume (PV) from baseline to Week 48</measure>
    <time_frame>Weeks 0 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in prostate specific antigen (PSA) from baseline to Weeks 24 and 48</measure>
    <time_frame>Weeks 0, 24 and 48</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in International Index of Erectile Function (IIEF) - Erectile Function (EF) domain scores from baseline to Weeks 4, 12, 24, 36 and 48</measure>
    <time_frame>Weeks 0, 4, 12, 24, 36 and 48</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Sexual Encounter Profile (SEP) Q2 and Q3 from baseline to Weeks 4, 12, 24, 36 and 48</measure>
    <time_frame>Weeks 0, 4, 12, 24, 36 and 48</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">654</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>DKF-313</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dutasteride 0.5mg + Tadalafil 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dutasteride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dutasteride 0.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tadalafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tadalafil 5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DKF-313</intervention_name>
    <description>Combination of dutasteride 0.5 mg and tadalafil 5 mg once daily for 48 weeks</description>
    <arm_group_label>DKF-313</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <description>Dutasteride 0.5 mg once daily for 48 weeks</description>
    <arm_group_label>Dutasteride</arm_group_label>
    <other_name>Avodart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Tadalafil 5 mg once daily for 48 weeks</description>
    <arm_group_label>Tadalafil</arm_group_label>
    <other_name>Cialis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DKF-313 placebo</intervention_name>
    <description>Once daily for 48 weeks</description>
    <arm_group_label>Dutasteride</arm_group_label>
    <arm_group_label>Tadalafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride placebo</intervention_name>
    <description>Once daily for 48 weeks</description>
    <arm_group_label>DKF-313</arm_group_label>
    <arm_group_label>Tadalafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil placebo</intervention_name>
    <description>Once daily for 48 weeks</description>
    <arm_group_label>DKF-313</arm_group_label>
    <arm_group_label>Dutasteride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male aged 45 to 80 years&#xD;
&#xD;
          -  BPH diagnosis&#xD;
&#xD;
          -  Voluntarily signed the informed consent form&#xD;
&#xD;
          -  Willing to participate in the study&#xD;
&#xD;
          -  Total IPSS 13 or greater at baseline&#xD;
&#xD;
          -  Prostate volume 30 cc or greater by TRUS at baseline&#xD;
&#xD;
          -  Qmax 4 to 15 mL/s and minimum voided volume 125 mL or greater at baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serum PSA 4 ng/mL or greater with a positive biopsy result&#xD;
&#xD;
          -  Malignant urogenital tumors including prostate cancer, bladder cancer, etc.&#xD;
&#xD;
          -  Previous prostatic surgery including TURP, balloon dilatation, thermotherapy and stent&#xD;
             replacement or other invasive procedures to treat prostate&#xD;
&#xD;
          -  Prostate biopsy within 4 weeks of screening&#xD;
&#xD;
          -  Use of alpha-blockers, alpha-agonists, phosphodiesterase type 5 (PDE5) inhibitors,&#xD;
             antidiuretics, anticholinergics, cholinergics, antispasmodics, nitrates or herbal&#xD;
             preparations affecting prostate within 4 weeks of screening, or 5-alpha reductase&#xD;
             inhibitors (5-ARIs) within 24 weeks of screening&#xD;
&#xD;
          -  Acute urinary retention within 12 weeks of screening&#xD;
&#xD;
          -  Any causes other than BPH resulting in urinary symptoms or changes in flow rate (e.g.&#xD;
             neurogenic bladder, bladder neck contracture, urethral stricture, bladder malignancy,&#xD;
             acute or chronic prostatitis, acute or chronic urinary tract infections)&#xD;
&#xD;
          -  Bladder postvoid residual 200 mL or greater&#xD;
&#xD;
          -  Anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or&#xD;
             Peyronie's disease) or conditions that might predispose to priapism (such as sickle&#xD;
             cell anemia, multiple myeloma, or leukemia)&#xD;
&#xD;
          -  Cardiovascular diseases such as myocardial infarction within 12 weeks of screening,&#xD;
             unstable angina or angina during sexual intercourse, heart failure (NYHA Class 2 or&#xD;
             higher) within 24 weeks of screening, uncontrolled arrhythmias, hypotension (&lt;90/50&#xD;
             mmHg) or uncontrolled hypertension (&gt;170/100 mmHg), or stroke within 24 weeks of&#xD;
             screening&#xD;
&#xD;
          -  Left ventricular outflow obstruction (e.g. aortic stenosis and idiopathic hypertrophic&#xD;
             subaortic stenosis)&#xD;
&#xD;
          -  Inherited disorders including galactose intolerance, Lapp lactase deficiency or&#xD;
             glucose-galactose malabsorption&#xD;
&#xD;
          -  Inherited retinal degeneration including retinitis pigmentosa&#xD;
&#xD;
          -  Vision loss in one eye due to non-arteritic anterior ischemic optic neuropathy (NAION)&#xD;
&#xD;
          -  Hypersensitivity to ingredients of investigational products&#xD;
&#xD;
          -  Alcohol or drug abuse or treating psychiatric disorders&#xD;
&#xD;
          -  Severe hepatic impairment (ALT or AST &gt; 3xULN)&#xD;
&#xD;
          -  Renal impairment with severe heart failure (serum creatinine &gt; 2xULN)&#xD;
&#xD;
          -  Uncontrolled diabetes (HbA1c 9% or greater)&#xD;
&#xD;
          -  Other investigational products or procedures within 12 weeks of screening&#xD;
&#xD;
          -  Plans to have a child or unwilling to comply with using medically accepted&#xD;
             contraception methods (such as surgical sterilization and condom) during the treatment&#xD;
             period&#xD;
&#xD;
          -  Not eligible due to other reasons at the investigator's discretion&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Choung-Soo Kim, M.D.</last_name>
    <phone>+82230103734</phone>
    <email>cskim@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Choung-Soo Kim, M.D.</last_name>
      <phone>+82230103734</phone>
      <email>cskim@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

